Sepracor's "Product And Use" Lunesta Ad To Be "Very Visible," Company Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Sepracor's Lunesta (eszopiclone) "product and use" ad campaign will "be very visible going forward," the company said during its April 25 earnings call
You may also be interested in...
Sepracor Sees Reward In Lunesta Promotion Push
Sepracor credits its intensive marketing sales and education programs as the key to new prescription growth in the third quarter despite the recent entry of two competing sleep aids.
Sepracor Sees Reward In Lunesta Promotion Push
Sepracor credits its intensive marketing sales and education programs as the key to new prescription growth in the third quarter despite the recent entry of two competing sleep aids.
Takeda's Rozerem Will Not Be First-Line Competitor To Ambien, Sanofi Says
Rozerem (ramelteon) launch could open a new segment of sleep aid market; Sanofi-Aventis predicts the insomnia agent's different mechanism of action will prevent it from competing directly with Ambien. Company is readying launch of Ambien CR to counter increased competition.